Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 4/11/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Daniel J. Drucker

Wrong Dr. Daniel J. Drucker?


Banting and Best Diabetes Centre at the University of Toronto

Employment History

Board Memberships and Affiliations

  • Director
    Best Diabetes Centre
  • Director
    U of T's Banting


  • M.D.
  • M.D. degree
    University of Toronto
169 Total References
Web References
Arisaph Pharmaceuticals : About : Scientific Advisory Board, 11 April 2014 [cached]
Daniel Drucker
Daniel J. Drucker, M.D., FRCPC Professor of Medicine, University of Toronto Director, Banting and Best Diabetes Centre, University of Toronto
Dr. Daniel J. Drucker is currently a Professor of Medicine, a member of the Endocrinology Division at the University of Toronto and Director of the Banting and Best Diabetes Centre at the University of Toronto. He is a foremost expert on the subject of enteric hormones. He received training in Internal Medicine and Endocrinology from Johns Hopkins Hospital in Baltimore and Toronto General Hospital, University of Toronto. Following completion of a research fellowship in Molecular Endocrinology at Massachusetts General Hospital, he established his own laboratory research program in 1987 in Toronto. His laboratory studies the synthesis, secretion, and mechanism of action of glucagon-like peptides. Specific areas of interest include how glucagon, GLP-1, GLP-2, and the enzyme DPP IV (dipeptidyl peptidase IV) regulate metabolic pathways that control food intake, nutrient absorption and disposal, and intestinal mucosal integrity. Dr. Drucker is an Editor of the journal Endocrinology, and the recipient of Outstanding Investigator Awards from the Canadian Diabetes Association, the Endocrine Society, and the Canadian Society for Clinical Investigation. He also has been elected to membership in the American Society for Clinical Investigation and the Association of American Physicians. Dr. Drucker received his M.D. degree from the University of Toronto in 1980 and received his FRCPC in Internal Medicine from the Royal College of Physicians and Surgeons of Canada in 1984.
/ News / Improving the health ..., 23 Jan 2012 [cached]
/ News / Improving the health of Canadians with diabetes-- Dr. Dan Drucker recognized for exceptional contributions to diabetes research and patient care in Canada (January 23, 2012-Toronto, ON) Dr. Daniel Drucker, Senior Investigator at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Professor of Medicine and Director of the Banting and Best Diabetes Centre at the University of Toronto, has received a 2011 CIHR/CMAJ Top Achievements in Health Research Award, in recognition of his internationally renowned achievements in diabetes patient care and research. Dr. Drucker was one of six recipients of the award, included among exceptional researchers in Canada whose achievements changed the course of health care delivery in their field of work.
For the third year, a peer-review panel of Canadian and international experts selected exceptional individuals including Dr. Drucker, based on the considerable health impact of their work to benefit Canadians and others worldwide. Among the six outstanding achievements selected, Dr. Drucker was one of only two who received special mentions for their highest-ranking successes. "I am very pleased that the hard work and accomplishments of our research team over two decades have led to a greater understanding of the biology of gut hormones, and in turn, the development of new drugs for the treatment of diabetes," said Dr. Drucker. New therapies are greatly improving blood sugar control for people with diabetes-an illness that impacts thousands of Canadians. The two most recently approved drug classes for the treatment of type 2 diabetes, DPP-4 inhibitors and GLP-1R agonists (both widely used in Canada and helping to improve glucose control and quality of life), are based substantially on Dr. Drucker's research. He is now investigating the cardiovascular effects of these drugs, in parallel with seven major clinical cardiovascular outcome studies that are underway to rigorously assess the safety of these new drugs in patients with diabetes and heart disease. Dr. Drucker also contributed to the testing of a new once-weekly treatment for type 2 diabetes that may complement the more common twice-daily injection of exenatide, an advance that has significantly improved the quality of life for people with diabetes. A clinician-scientist at Mount Sinai since 2007, Dr. Drucker's leadership and achievements in diabetes research at the hospital have received both national and international recognition.
This reflects the remarkable impact Dr. Drucker has had on patients suffering from diabetes." Later this year, Dr. Drucker will become the first and only Canadian to receive the Claude Bernard Lecture/Award of the European Association for the Study of Diabetes (EASD), which is thehighest scientific achievement award of the EASD. He holds the Canada Research Chair in Regulatory Peptides; received the Prix Galien Canada Research Award in 2008 for his substantial contribution to the diagnosis, prevention or treatment of diseases; and the 2009 Clinical Investigator Award from The Endocrine Society. The incidence of type 2 diabetes has reached epidemic proportions worldwide and is a leading cause of heart disease, stroke, blindness, kidney failure and limb amputation. Several studies have shown that lifestyle changes and appropriate pharmacologic therapy can significantly reduce the development of type 2 diabetes in people at risk of the disease. Dr. Drucker's significant research discoveries mean improved health for millions of patients with type 2 diabetes worldwide. His key findings led to the development of several new classes of therapies for these patients. The new therapies reduced the need for self-monitoring of blood glucose levels and lowered the risk of hypoglycemia and weight gain. Currently, Dr. Drucker's lab at the Lunenfeld focuses on understanding the biology of glucagon-like peptides.
Receptos Inc. - Scientific Advisory Board, 23 Aug 2014 [cached]
Daniel J. Drucker M.D.
Professor of Medicine in the Division of Endocrinology, Department of Medicine, University of Toronto
UHN: News, 7 Aug 2007 [cached]
"The commitment and resources deployed under this new partnership will significantly enhance our ability to achieve a global impact in research, education and clinical care of diabetes," said Dr. Daniel Drucker, Director of the BBDC.
In a study published by the ..., 8 Dec 2012 [cached]
In a study published by the Lancet journal today, Toronto researcher Dr. Daniel Drucker reported that a new once-weekly treatment for type 2 diabetes could replace the more common twice-daily injection.
"Over two million Canadians have diabetes," said Dr. Daniel Drucker, clinician-scientist and Senior Investigator at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital.
Dr. Drucker has studied the gut hormone GLP-1 for over 20 years.
"Dr. Drucker is a world-expert in the development of peptide hormone-based therapies for the treatment of human disease and this is an excellent example of moving discovery through to therapeutic application."
Other People with the name "Drucker":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.